Clearance of JC polyomavirus from cerebrospinal fluid following treatment with interleukin‐2 and pembrolizumab in an individual with progressive multifocal leukoencephalopathy and no underlying immune deficiency syndrome
暂无分享,去创建一个
G. Fink | A. Wellstein | Roland Martin | M. Wattjes | M. Schlamann | S. Silling | C. Warnke | M. Schroeter | B. von Tresckow | O. Adams | F. Schweitzer | S. Borchmann | Yasemin Goereci
[1] R. D. Du Pasquier. Pembrolizumab as a treatment for PML? , 2019, Neurology: Neuroimmunology & Neuroinflammation.
[2] C. Mengelle,et al. Treatment of Progressive Multifocal Leukoencephalopathy with Nivolumab. , 2019, The New England journal of medicine.
[3] C. Weiller,et al. Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab. , 2019, The New England journal of medicine.
[4] Bryan R. Smith,et al. Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy , 2019, The New England journal of medicine.
[5] H. Hartung,et al. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab‐associated progressive multifocal leukoencephalopathy , 2014, Annals of neurology.
[6] E. Frohman,et al. Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature. , 2016, Therapeutic advances in neurological disorders.